Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-1380
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism ; volume:6 ; number:1 ; day:16 ; month:7 ; year:2013 ; pages:1-9 ; date:12.2013
International journal of emergency medicine ; 6, Heft 1 (16.7.2013), 1-9, 12.2013
- Urheber
-
Goldstein, Patrick
Elalamy, Ismaïl
Huber, Kurt
Danchin, Nicolas
Wiel, Eric
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1865-1380-6-25
- URN
-
urn:nbn:de:101:1-2019062923430023891267
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Goldstein, Patrick
- Elalamy, Ismaïl
- Huber, Kurt
- Danchin, Nicolas
- Wiel, Eric
- SpringerLink (Online service)
Ähnliche Objekte (12)
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients